In Brief: Hydrocortisone topical ointment 2.5%
Executive Summary
Hydrocortisone topical ointment 2.5%: FDA determines Upjohn's Cortef was not withdrawn for safety or efficacy reasons, and the agency will accept ANDAs for the product, according to a May 21 Federal Register notice. Reed & Carnick submitted a citizen petition in May 1995 requesting an agency determination on Cortef's withdrawal. Upjohn received approval for the product in 1953 and withdrew it from the market in 1991...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth